North Macedonia vs Suriname: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
North Macedonia
0.2%
in 2024
Suriname
0.2%
in 2024
North Macedonia rank
98th
Suriname rank
98th
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- North Macedonia
- Suriname
How they compare
North Macedonia currently reports 0.2% against 0.2% in Suriname, a difference of 0.0%.
Across all 10 years both countries report, Suriname has been ahead every year.
North Macedonia ranks 98th and Suriname ranks 98th of 246 countries.
Suriname has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | North Macedonia | Suriname | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.1% | 0.2% | 0.1% | Suriname |
| 2020s | 0.1% | 0.2% | 0.1% | Suriname |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, North Macedonia or Suriname?
- North Macedonia, at 0.2% against 0.2% in Suriname as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between North Macedonia and Suriname?
- 0.0%, with North Macedonia ahead.
- How many years of comparable data are there for North Macedonia and Suriname?
- 10 years are reported by both, from 2015 to 2024.
- How do North Macedonia and Suriname rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- North Macedonia ranks 98th and Suriname ranks 98th of 246 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.